Quarterly report pursuant to Section 13 or 15(d)

Royalty Purchase Agreements - Bioasis (Details)

v3.20.1
Royalty Purchase Agreements - Bioasis (Details)
$ in Thousands
 3 Months Ended 12 Months Ended
Feb. 25, 2019
USD ($)
agreement
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2019
USD ($)
Licensing and other arrangements        
Payments to acquire milestones and royalties     $ 300  
Contingent consideration under royalty purchase agreements   $ 75   $ 75 [1]
Long-term royalty receivables   34,375   34,375 [1]
Changes in estimated fair value of contingent consideration   0    
Payments of contingent consideration   0    
Impairment of long-term royalty receivable   0   $ 0
Bioasis Technologies Inc | Royalty Purchase Agreement        
Licensing and other arrangements        
Percentage of option to purchase royalty right on future license agreements 1.00%      
Number of future license agreements under optional purchase right | agreement 2      
Obligation upon exercise of options per licensed product, second agreement $ 300      
Obligation upon exercise of options per licensed product, third agreement 400      
Payments to acquire milestones and royalties 300      
Long-term royalty receivables 400      
Estimated fair value of contingent consideration 100      
Payments of contingent consideration   0    
Impairment of long-term royalty receivable   $ 0    
Bioasis Technologies Inc | Royalty Purchase Agreement | Maximum        
Licensing and other arrangements        
Potential future cash payments $ 200      
[1] The consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10K for the year ended December 31, 2019.